Is Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They fail miserably sometimes, but historically their consensus stock picks outperformed the market after adjusting for known risk factors.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) shareholders have witnessed an increase in support from the world’s most elite money managers lately. THLD was in 13 hedge funds’ portfolios at the end of the third quarter of 2015. There were 9 hedge funds in our database with THLD holdings at the end of the previous quarter. At the end of this article we will also compare THLD to other stocks, including Meta Financial Group Inc. (NASDAQ:CASH), Asanko Gold Inc (NYSEMKT:AKG), and Sodastream International Ltd (NASDAQ:SODA) to get a better sense of its popularity.
According to most traders, hedge funds are seen as underperforming, old financial vehicles of years past. While there are more than 8000 funds with their doors open at the moment, We choose to focus on the bigwigs of this group, approximately 700 funds. These investment experts manage bulk of the smart money’s total asset base, and by tailing their best investments, Insider Monkey has formulated several investment strategies that have historically defeated Mr. Market. Insider Monkey’s small-cap hedge fund strategy outpaced the S&P 500 index by 12 percentage points a year for a decade in their back tests.
Now, we’re going to view the key action surrounding Threshold Pharmaceuticals, Inc. (NASDAQ:THLD).
Hedge fund activity in Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)
Heading into Q4, a total of 13 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 44% from one quarter earlier. With hedgies’ capital changing hands, there exists a few key hedge fund managers who were upping their stakes substantially (or already accumulated large positions).
When looking at the institutional investors followed by Insider Monkey, Julian Baker and Felix Baker’s Baker Bros. Advisors has the most valuable position in Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), worth close to $11.9 million, corresponding to 0.1% of its total 13F portfolio. The second largest stake is held by Millennium Management, led by Israel Englander, holding an $6.3 million position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Some other hedge funds and institutional investors with similar optimism comprise Phill Gross and Robert Atchinson’s Adage Capital Management, Jim Simons’ Renaissance Technologies and D. E. Shaw’s D E Shaw.